Merck Sharp & Dohme LLC, known globally as MSD, is a research-intensive biopharmaceutical company with a history spanning more than 130 years. The company develops medicines and vaccines for both people and animals, operating across the biopharmaceuticals, animal health, and veterinary medicine sectors. Its technical work encompasses drug discovery, vaccine development, and veterinary solutions, with operations in the United States and Canada.
The company's historical contributions to public health are notable. Its breakthrough with streptomycin helped reduce tuberculosis deaths by nearly 50% by 1950. MSD aspires to be the premier research-intensive biopharmaceutical company, guided by the philosophy that medicine is for the people, not for the profits. The organisation follows the science where it can make the greatest difference.
MSD's work spans both human and animal health, positioning it at the intersection of pharmaceutical research and public-health outcomes. The company maintains a long-standing focus on translating scientific research into treatments and preventive therapies across its core therapeutic areas.
